Yahoo Finance·2025-12-28 15:59Group 1 - Sanofi has announced a definitive agreement to acquire Dynavax Technologies Corporation for $15.50 per share, totaling approximately $2.2 billion in equity value [1][3] - The acquisition aligns with Sanofi's strategy to expand its presence in adult immunization, particularly through Dynavax's hepatitis B vaccine, HEPLISAV-B, which is the only two-dose adult hepatitis B vaccine approved in the US [2][3] - The deal has been unanimously approved by Dynavax's board and is expected to close in the first quarter of 2026, with no impact on Sanofi's financial guidance for 2025 [3] Group 2 - Analysts have a positive outlook on Sanofi, with a 12-month price target reflecting more than 26% upside from the current level, and a recent Hold rating with a price target of $57 from TD Cowen [4]